IC
ITOS

Ikarian Capital’s iTeos Therapeutics ITOS Stock Holding History

Ikarian Capital’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3,056
Closed -$3.35M – 157
2023
Q3 		$3.35M Buy
+3,056
New +$39.1K 0.4% 62
2022
Q3 		– Sell
-100,000
Closed -$2.06M – 137
2022
Q2 		$2.06M Buy
+100,000
New +$2.37M 0.38% 57

Other funds holding ITOS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ikarian Capital's ITOS Position: Q2 2025 in Review

Ikarian Capital sold out of iTeos Therapeutics (ITOS) in Q2 2025, closing a stake of 78,585 shares — an estimated $469K sold.

Ikarian Capital first reported a position in ITOS in Q3 2023 and held it in 7 quarters. The position peaked at $3.79M in Q4 2023. 136 funds tracked by Wall St. Rank hold ITOS as of Q2 2025.

  • Ikarian Capital reported no remaining iTeos Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Ikarian Capital sold 78,585 iTeos Therapeutics shares in Q2 2025, an estimated $469K.
  • Ikarian Capital first reported a position in iTeos Therapeutics in Q3 2023 and held it in 7 quarters.
  • Ikarian Capital's iTeos Therapeutics position peaked at $3.79M in Q4 2023.
  • 136 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2025.

Based on Ikarian Capital's 13F filing for Q2 2025, filed 14 Aug 2025.